RxDoctor Payments Data

Bharathi Ramaiah, MD

Gastroenterology · Tavares, FLNPI 1164411484

Payments from drug & device makers

$3,025in general payments, 2019–2025

Across 178 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$237
  • Ardelyx, Inc.$154
  • Medtronic$127
  • Intercept Pharmaceuticals, Inc.$106
  • Vivus LLC$83
  • plus $821 from 24 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$2,97298%
  • Education$381%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,025 in reported general payments places this provider in the 45th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$453,019
Medicare patients
1,252
Services billed
5,051

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide82$71,210
CreonLipase/Protease/Amylase21$60,452
XifaxanRifaximin15$44,154
ZenpepLipase/Protease/Amylase11$41,421
ClenpiqSod Picosulf/Mag Ox/Citric Ac226$38,734
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates391$24,066
Mesalamine45$23,301
TrulancePlecanatide15$13,169
Ursodiol31$7,009
Mesalamine ErMesalamine29$5,712
Colesevelam Hcl55$4,800
Pantoprazole Sodium288$4,318
Famotidine164$2,569
Colestipol Hcl37$2,563
Omeprazole150$2,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,497$131,661103 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$237$57,32330 claims
Aimmune Therapeutics, Inc.Zenpep$20$41,42111 claims
Ferring Pharmaceuticals Inc.Clenpiq$26$38,734226 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Tavares

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →